EUVIMEDEUVIMED entdecken
Crossref

Antipsychotic treatment and psychosocial functioning in schizophrenia – results from Romanian cohort of EUFEST study

Valentin P. Matei, Alexandra Mihailescu, Traian Purnichi, Ruxandra M. Al-Bataineh

Romanian Journal of Psychiatry and Psychotherapy · 2016

DOI: 10.37897/rjpp.2016.2.4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Romanian Journal of Psychiatry and Psychotherapy, 2016. Verfasst von Valentin P. Matei und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Schizophrenia represents a chronic and debilitating illness listed by the international organisms as top priority for public health actions to reduce disability and improve the function and quality of life for people living with chronic illness.

Objective

The aim of this study was to compare psychosocial functioning of schizophrenic patients after 1 year of neuroleptic treatment in a first episode schizophrenia population treated with atypical or typical antipsychotics.

Methods

Procedures of the European First Episode Schizophrenia Trial study (EUFEST) have been previously described. Data analyzed in this paper refers to Romanian patients (N = 113) included in the EUFEST study. Psychosocial functioning was assessed by Global Assessment of Functioning (GAF). GAF questionnaire was applied at baseline and at 1, 2, 3, 6, 9 and 12 months (end of study).

Results

Mean value at 1 year compared with baseline was 76.88 (±16.20) vs. 39.06 (±13.56) for Haloperidol, 75.58 (±18.41) vs. 40.67 (±12.71) for Olanzapine, 78.57 (±10.15) vs. 37.65 (±17.05) for Quetiapine, 82.35 (±10.16) vs. 38.24 (±12.52) for Amisulpride, 76.11 (±9.47) vs. 38.33 (±10.26) for Ziprasidone. Statistical comparison with ANOVA revealed no statistically significant differences, p = 0.533. The improvement in functionality in patients did not differ between antipsychotics from one evaluation to another. During the antipsychotic treatment, the psychosocial functioning of patients improved significantly more during the first 6 months, irrespective of treatment arms. After that, the improvement continued to develop, but at a slower pace.

Conclusions

Our study didn't support the superiority of atypical neuroleptics versus classical ones regarding functionality in first episode schizophrenic patients. The improvement starts fast with both classes of drugs and the larger part of improvement in functionality took part during the first 3−6 months of treatment.

Zitieren

APA

Matei, V. P., Mihailescu, A., Purnichi, T., & Al-Bataineh, R. M. (2016). Antipsychotic treatment and psychosocial functioning in schizophrenia – results from Romanian cohort of EUFEST study. Romanian Journal of Psychiatry and Psychotherapy. https://doi.org/10.37897/rjpp.2016.2.4

Vancouver

Matei VP, Mihailescu A, Purnichi T, Al-Bataineh RM. Antipsychotic treatment and psychosocial functioning in schizophrenia – results from Romanian cohort of EUFEST study. Romanian Journal of Psychiatry and Psychotherapy. 2016. doi:10.37897/rjpp.2016.2.4

BibTeX
@article{Matei2016,
  author = {Matei, Valentin P. and Mihailescu, Alexandra and Purnichi, Traian and Al-Bataineh, Ruxandra M.},
  title = {Antipsychotic treatment and psychosocial functioning in schizophrenia – results from Romanian cohort of EUFEST study},
  journal = {Romanian Journal of Psychiatry and Psychotherapy},
  year = {2016},
  doi = {10.37897/rjpp.2016.2.4}
}
Kostenlos starten →